Cancer Math That Doesn't Add Up

Posted on May 3rd, 2012 by

Combining existing drug therapies has long been an area of interest for cancer researchers. If one therapy works well, could adding another drug work even better?...Dr. Alberts said the other study involving bevacizumab had similar results. "This is important as it means that patients with resected stage 3 colon cancer should only receive FOLFOX. It also means that what works in metastatic colon cancer will not necessarily work in resected stage 3 colon cancer, a paradigm that we have used for many years," said Dr. Alberts, who is also medical director of Mayo Clinic Cancer Center Clinical Research Office.


Daily RX by Laurie Stonham

Tags: Cancer, Daily RX, FOLFOX, Mayo Clinic Cancer Center, Pharmacology, Research

You must be logged-in to the site to post a comment.

Contact Us · Privacy Policy